<table>
<thead>
<tr>
<th>Type of Cancer</th>
<th>Open Immunotherapy Clinical Trials</th>
<th>You may be eligible if:</th>
<th>Location</th>
</tr>
</thead>
</table>
| Lung (Non-Small Cell Carcinoma) | **Incyte BMS INCB24360-204** A Phase I/II Study of the Safety, Tolerability, and Efficacy of INCB24360 Administered in Combination With Nivolumab in Select Advanced Cancers | • 18 years or older  
• Diagnosis of stage IIIB or IV, or recurrent NSCLC  
• Received only one prior systemic regimen and contained a platinum agent  
• Disease that can be measured on a CT scan  
• Otherwise healthy | Sioux Falls, SD  
Fargo, ND |
| | **CTSU S1400 (MAP)** Phase II/Ii Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer | • 18 years or older  
• Diagnosis of squamous cell lung carcinoma  
• Disease that can be measured on a CT scan  
• Received at least one line of platinum-based chemotherapy  
• Otherwise healthy | Sioux Falls, SD  
Fargo, ND  
Bismarck, ND  
Bemidji, MN |
| | **ECOG-ACRIN E4512** A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein | • 18 years or older  
• Must have had complete surgical resection  
• Otherwise healthy | Sioux Falls, SD  
Fargo, ND  
Bismarck, ND  
Bemidji, MN |
| | **Keynote 189** A Randomized, Double-Blind, Phase III Study of Platinum + Pemetrexed Chemotherapy With or Without Pembrolizumab (MK-3475) in First Line Metastatic Non-squamous Non-small Cell Lung Cancer Subjects | • 18 years or older  
• Diagnosis of stage IV non-squamous non-small cell lung carcinoma  
• Disease that can be measured on a CT scan  
• No prior treatment for advanced/metastatic NSCLC  
• Otherwise healthy | Sioux Falls, SD  
Fargo, ND  
Bismarck, ND  
Bemidji, MN |
| | **Alliance A151216** Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST) | • 18 years or older  
• Diagnosis of stage IB-IIIA NSCLC  
• Must have complete resection  
• Must have tissue available for EGFR/ALK testing  
• Otherwise healthy | Sioux Falls, SD  
Fargo, ND  
Bismarck, ND  
Bemidji, MN |
| | **BMS CA209370 Checkmate 370** Master Protocol of Phase I/II Studies of Nivolumab in Advanced NSCLC using Nivolumab as maintenance after Induction Chemotherapy or as first-line Treatment Alone or in Combination with Standard of Care Therapies (CA209370) | • 18 years or older  
• Diagnosis of stage IV squamous or non-squamous NSCLC  
• Disease that can be measured on a CT scan  
• Otherwise healthy | Sioux Falls, SD  
Bismarck, ND |
| Head and Neck (Squamous Cell Carcinoma) | **CheckMate 358** Non-Comparative, Two-Cohort, Single-Arm, Open-Label, Phase I/II Study of Nivolumab (BMS-936558) in Subjects with Virus-Positive and Virus-Negative Solid Tumors | • 18 years or older  
• Diagnosis of HNSCC  
• Are eligible for surgical resection or have progressive metastatic/recurrent disease  
• Otherwise healthy | Sioux Falls, SD |
| | **SH MISP203** Phase Ib Study of Pembrolizumab in Combination with Chemo Radiotherapy (CRT) for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN) | • 18 years or older  
• Diagnosis of HNSCC  
• Are eligible for curative intent treatment  
• Otherwise healthy | Sioux Falls, SD  
Fargo, ND  
Bismarck, ND |
| | **Keynote 048** Phase III Clinical Trial of Pembrolizumab in First Line Treatment of Recurrent/Metastatic HNSCC | • 18 years or older  
• Diagnosis of HNSCC  
• Not receiving any other treatment  
• Disease that can be measured on a CT scan  
• Otherwise healthy | Sioux Falls, SD  
Fargo, ND |
| | **Incyte BMS INCB24360-204** A Phase I/II Study of the Safety, Tolerability, and Efficacy of INCB24360 Administered in Combination With Nivolumab in Select Advanced Cancers | • 18 years or older  
• Diagnosis of metastatic or recurrent squamous cell carcinoma  
• Received no more than two prior systemic regimens for advanced disease  
• Disease that can be measured on a CT scan  
• Otherwise healthy | Sioux Falls, SD  
Fargo, ND |
| Colorectal | **Keynote 177** Phase III Study of Pembrolizumab vs Chemotherapy in Microsatellite Instability- High or Mismatched Repair Deficient Colorectal Carcinoma | • 18 years or older  
• Diagnosis of colorectal carcinoma  
• Has not received prior systemic treatment for stage IV colorectal cancer  
• Disease that can be measured on a CT scan  
• Otherwise healthy | Sioux Falls, SD |
<table>
<thead>
<tr>
<th>Type of Cancer</th>
<th>Open Immunotherapy Clinical Trials</th>
<th>You may be eligible if:</th>
<th>Location</th>
</tr>
</thead>
</table>
| Gastric or Gastroesophageal | **Keynote 181**<br>A Randomized Open-label Phase III Study of Single Agent Pembrolizumab vs. Physicians’ Choice of Single Agent Paclitaxel or Docetaxel in Subjects with Advanced/Metastatic Squamous Cancer and Adenocarcinomas of the Esophagus That Have Progressed After First-Line Standard Therapy | - 18 years or older  
- Diagnosis of adenocarcinoma or squamous cell carcinoma of the esophagus or Siewert type I adenocarcinoma of the Esophagus  
- Disease that can be measured on a CT scan  
- Previously treated with first-line standard therapy  
- Otherwise healthy                                                                                                                                                                                                                                                                  | Sioux Falls, SD Fargo, ND |
| Gynecologic Cancer        | **CheckMate 358 (Cervical)**<br>Non-Comparative, Two-Cohort, Single-Arm, Open-Label, Phase II/II Study of Nivolumab (BMS-936558) in Subjects with Virus-Positive and Virus-Negative Solid Tumors | - 18 years or older  
- Diagnosis of stage II to IVA disease  
- Are eligible for planned surgery or chemotherapy/radiation therapy  
- Otherwise healthy                                                                                                                                                                                                                                                                     | Sioux Falls, SD |
| Prostate                  | **Keynote 199**<br>Phase II Trial of Pembrolizumab (MK-3475) in Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated with Chemotherapy | - 18 years or older  
- Diagnosis of prostate cancer  
- Has received chemotherapy and endocrine therapy for their cancer  
- Disease that can be measured on a CT scan or disease that is considered non-measurable  
- Otherwise healthy                                                                                                                                                                                                                                                                    | Sioux Falls, SD Fargo, ND |
| Renal Cell                | **Keynote 426**<br>A Phase III randomized, open-label, clinical trial to study the efficacy and safety of pembrolizumab (MK3475) in combination with axitinib versus sunitinib monotherapy as a first-line treatment for locally advanced/metastatic renal cell carcinoma (mRCC) | - 18 years or older  
- Diagnosis of stage III or IV melanoma that has been completely removed  
- Otherwise healthy                                                                                                                                                                                                                                                                                     | Sioux Falls, SD |
| Melanoma                  | **CTSU S1404**<br>A Phase III Randomized Trial Comparing Physician/Patient Choice of High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma | - 18 years or older  
- Diagnosis of stage III or IV melanoma that has been completely removed  
- Otherwise healthy                                                                                                                                                                                                                                                                                      | Sioux Falls, SD Fargo, ND Bismarck, ND Bemidji, MN |
|                           | **ECOG-ACRIN EA6134**<br>A Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab Followed by Dabrafenib + Trametinib at Progression in Patients with Advanced BRAFV600E and BRAF v600K Melanoma | - 18 years or older  
- Diagnosis of unresectable stage III or IV melanoma  
- Disease that can be measured by CT scan  
- Must have BRAF v600E or BRAF v600K mutations  
- Otherwise healthy                                                                                                                                                                                                                                                                              | Sioux Falls, SD Fargo, ND Bismarck, ND Bemidji, MN |
|                           | **ECOG-ACRIN EA6141**<br>Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma | - 18 years or older  
- Diagnosis of unresectable stage III or IV melanoma  
- Disease that can be measured by CT scan  
- Must have known BRAF mutational status (wild-type or mutated)  
- Otherwise healthy                                                                                                                                                                                                                                                                                         | Sioux Falls, SD Fargo, ND Bismarck, ND Bemidji, MN |
|                           | **Incyte BMS INCB24360-204**<br>A Phase I/II Study of the Safety, Tolerability, and Efficacy of INCB24360 Administered in Combination with Nivolumab in Select Advanced Cancers | - 18 years or older  
- Diagnosis of unresectable or stage IV melanoma  
- Must have known BRAF mutational status of V600E  
- Have received no treatment or only one prior systemic treatment  
- Disease that can be measured on a CT scan  
- Otherwise healthy                                                                                                                                                                                                                                                                               | Sioux Falls, SD Fargo, ND |
| Breast                    | **Keynote 119**<br>A Randomized Open-Label Phase III Study of Single Agent Pembrolizumab versus Single Agent Chemotherapy Per Physicians Choice for Metastatic Triple Negative Breast Cancer (mTNBC) | - 18 years or older  
- Have received one or two prior systemic treatments for metastatic breast cancer  
- Diagnosis of triple negative breast cancer  
- Disease that can be measured by CT scan  
- Otherwise healthy                                                                                                                                                                                                                                                                                         | Sioux Falls, SD |
|                           | **Keynote 355**<br>A Randomized, Double-Blind, Phase III Study of Pembrolizumab (MK-3475) plus Chemotherapy vs Placebo plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer | - 18 years or older  
- Have locally recurrent inoperable breast cancer  
- Confirmed triple negative breast cancer  
- Disease that can be measured by CT scan  
- Otherwise healthy                                                                                                                                                                                                                                                                                      | Sioux Falls, SD Fargo, ND |
|                           | **Moonshot-NantBioScience CMS-005**<br>Phase I Study of ADS [E1-, E2B-]-HER2/NEU Vaccine (ETBX-021) in Subjects with Unresectable Locally Advanced or Metastatic HER2-Low-Expressing (IHC 1+/2+) Breast Cancer | - 18 years or older  
- Have unresectable locally advanced or metastatic breast cancer  
- Confirmed HER2 of IHC 1+ or 2+  
- Otherwise healthy                                                                                                                                                                                                                                                                                     | Sioux Falls, SD |
<table>
<thead>
<tr>
<th>Type of Cancer</th>
<th>Open Immunotherapy Clinical Trials</th>
<th>You may be eligible if:</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Merkel Cell Skin Cancer</strong></td>
<td><strong>CheckMate 358</strong>&lt;br&gt;Non-Comparative, Two-Cohort, Single-Arm, Open-Label, Phase I/II Study of Nivolumab (BMS-936558) in Subjects with Virus-Positive and Virus-Negative Solid Tumors</td>
<td>• 18 years or older&lt;br&gt;• Eligible for neo-adjuvant treatment&lt;br&gt;• Otherwise healthy</td>
<td>Sioux Falls, SD</td>
</tr>
<tr>
<td><strong>Non-Hodgkin Lymphomas</strong></td>
<td><strong>Incyte BMS INCB24360-204</strong>&lt;br&gt;A Phase I/II Study of the Safety, Tolerability, and Efficacy of INCB24360 Administered in Combination with Nivolumab in Select Advanced Cancers</td>
<td>• 18 years or older&lt;br&gt;• Diagnosis of relapsed or refractory DLBCL&lt;br&gt;• Not a candidate for curative therapy or hematopoietic stem cell transplantation&lt;br&gt;• Disease that can be measured on a CT scan&lt;br&gt;• Otherwise healthy</td>
<td>Sioux Falls, SD Fargo, ND</td>
</tr>
</tbody>
</table>